Drug Combination Details
| General Information of the Combination (ID: C01747) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Apatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p-Akt and p-ERK, and upregulating the expression of Caspase-3 and Bax. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells. Oncol Lett. 2018 Jul;16(1):353-361. | |||
